1. Home
  2. RANI vs PFO Comparison

RANI vs PFO Comparison

Compare RANI & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

N/A

Current Price

$1.12

Market Cap

126.8M

Sector

Health Care

ML Signal

N/A

Logo Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

PFO

Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

N/A

Current Price

$8.99

Market Cap

117.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
RANI
PFO
Founded
2012
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
126.8M
117.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RANI
PFO
Price
$1.12
$8.99
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
925.4K
30.3K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
6.51%
EPS Growth
21.05
N/A
EPS
N/A
N/A
Revenue
$1,028,000.00
N/A
Revenue This Year
$414.59
N/A
Revenue Next Year
$30.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$8.01
52 Week High
$3.87
$9.90

Technical Indicators

Market Signals
Indicator
RANI
PFO
Relative Strength Index (RSI) 35.82 27.23
Support Level $1.07 $8.01
Resistance Level $1.54 $9.33
Average True Range (ATR) 0.07 0.09
MACD -0.03 -0.02
Stochastic Oscillator 15.71 25.56

Price Performance

Historical Comparison
RANI
PFO

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks: